Here are five things to know about the transaction and the company’s stock:
• The shares were sold at an average price of $44.82, for a total value of $238,128.
• Mr. Lukianov now directly owns 328,367 shares of the company’s stock, valued at approximately $14.7 million.
• NuVasive currently has an average rating of “buy” and a consensus price target of $52.27.
• The company has a one-year low of $31.35 and a one-year high of $51.23.
• NuVasive’s market cap is $2.136 billion.
More articles on devices:
FDA approves Tornier’s shoulder system, aims to improve shoulder arthroplasty — 4 things to know
Piper Jaffray assumes Integra LifeSciences coverage — 5 things to know
Zimmer sells $7.65B of senior notes for Biomet merger — 7 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.